ORNA Lipid AX-6
Version 1.a5449a91 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | ORNA Lipid AX-6 |
| Synonyms | ORNA Lipid AX 6，AX6 |
| SMILES | CCCCCCCCOC(CCC(=O)OCC12CC3CC(COC(=O)CCCN(CC)CC)(C1)CC(COC(=O)CCC(OCCCCCCCC)OCCCCCCCC)(C3)C2)OCCCCCCCC |
| Formula | C61H113O10N |
| M.Wt | 1,020.57 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Not available |
AX6 is an ionizable lipid in the F32 LNP formulation, engineered by ReNAgade/Orna Therapeutics for targeted mRNA delivery to T cells. AX-6's unique bridged bicyclic/polycyclic core with a tertiary amine group enables pH-dependent protonation and endosomal escape, while C14-C18 hydrophobic tails (optionally branched/fluorinated) enhance bilayer stability and mRNA encapsulation. Demonstrating exceptional T-cell tropism, AX6 achieves high transfection efficiency in CD4+/CD8+ T cells (validated in NHP/humanized models) with minimal toxicity. Compared to clinical benchmarks (SM-102, ALC-0315), its rigid core offers superior serum stability and immune-cell specificity, positioning it as an ideal candidate for CAR-T/NK therapies and next-gen vaccines. The F32 LNP system's proven efficacy (e.g., in vivo B-cell depletion) underscores AX 6's transformative potential for cell engineering and immunotherapies.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →